3-V Biosciences raises $28.5m in Series D

Oncology and infectious diseases company 3-V Biosciences has raised $28.5m in a Series D venture round co-led by NEA, Kleiner Perkins, Rock Springs Capital Management and Ally Bridge Group.

Oncology and infectious diseases company 3-V Biosciences has raised $28.5m in a Series D venture round co-led by NEA, Kleiner Perkins, Rock Springs Capital Management and Ally Bridge Group.

Proceeds from the capital infusion will enable 3-V to advance development of its experimental oncology drug TVB-2640, an oral fatty acid synthase (FASN)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By 

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.